GÉTICA 2021

5 [ F I T C á n c e r - 7 ] of these kinds of hyperinflammation syn- dromes. Considering elevated serum concentration of IL-6 and CPR in patients admitted in ICUs department, we started to use monoclonal antibodies against IL6, above all tocilizumab. In Italy we started on March, 19th a phase II study (NCT04317092) which enrolled 330 pa- tients in 24 hours, with the ability of tocilizum- ab to reduce the one-month mortality rate as main endpoint which was met. Other drugs active in reducing the CRS are at moment in clinical trial or expanded access program like JAK inhibitors, complement inhibitors, toll like receptor inhibitors and others. NOTAS